Coronary Artery Disease (CAD) Clinical Trial
Official title:
Effectiveness and Safety of Low Dose Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk
Verified date | September 2023 |
Source | Maatschap Cardiologie Zwolle |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
Registry to describe the impact in terms of effectiveness and safety of the combination treatment of rivaroxaban 2.5 mg twice daily with aspirin on clinical outcomes and practices in a real-life Dutch patient population that are at high risk of ischemic events.
Status | Completed |
Enrollment | 645 |
Est. completion date | September 13, 2023 |
Est. primary completion date | September 13, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult (=18 years) patient. - Diagnosis of CAD and/or PAD and high risk of ischemic events. - Patients at high risk of ischaemic events include the following: - CAD + PAD - CAD + Recurrent MI (Previous MI followed by second MI) - CAD + diabetes mellitus (all types) - CAD + chronic kidney disease with eGFR 30-59 ml/min/1.73 m2 (CKD-EPI formula) - CAD + heart failure (ejection fraction =30% - 50%) and New York Heart Association (NYHA) class I or II;) - CAD + CHA2DS2VaSc = 3 (for men) or = 4 (for women) - Patients can only be enrolled in the study if the decision to treat with rivaroxaban plus ASA has been made by the treating physician in advance and independent of study inclusion, however within 4 weeks prior to study inclusion. - Treatment according to local marketing authorization, with rivaroxaban 2.5 mg [BID] and 80mg ASA / 100mg Carbasalate calcium. Treatment of rivaroxaban started within 4 weeks prior or 4 weeks after study inclusion. - Patients who are willing to participate in this study (signed informed consent). Exclusion Criteria: - Hypersensitivity/allergy and known contraindication to ASA/Carbasalate calcium or rivaroxaban - Patients with recent major bleeding, active bleeding, or history with: - History of major clinical bleeding or known coagulopathy - History of intracerebral mass, aneurysm, arteriovenous malformation, or hemorrhagic stroke - Known severe liver dysfunction - Patients that have received any organ transplant or await any organ transplant - Patient with anemia (Hb < 6.0 mmol/L) - Patient with active malignancy - Patients with ejection fraction < 30% and/or New York Heart Association (NYHA) class III or IV - Patients with eGFR < 30 ml/min/1.73m2 or undergoing dialysis - Patients with liver failure accompanied with coagulopathy ( incl. Child-Pugh B and C) - Patients with concomitant use of other anticoagulants or antiplatelet drugs - Pregnant or lactating female - Patients currently participating in another investigational drug or drug-coated device study |
Country | Name | City | State |
---|---|---|---|
Netherlands | OLVG | Amsterdam | |
Netherlands | Rijnstate hospital | Arnhem | |
Netherlands | Jeroen Bosch hospital | Den Bosch | |
Netherlands | Haaglanden Medisch Centrum | Den Haag | |
Netherlands | Hagaziekenhuis | Den Haag | |
Netherlands | Medisch Spectrum Twente | Enschede | |
Netherlands | Zuyderland Medical Center | Heerlen | |
Netherlands | Isala Klinieken, location Meppel | Meppel | |
Netherlands | St. Antonius hospital | Nieuwegein | |
Netherlands | Elisabeth-Tweesteden hospital | Tilburg | |
Netherlands | VieCuri | Venlo | |
Netherlands | Isala hospital | Zwolle |
Lead Sponsor | Collaborator |
---|---|
Maatschap Cardiologie Zwolle | Diagram B.V. |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary Outcome Measures | The primary efficacy endpoint is a composite of 1) Major Adverse Cardiovascular Events (MACE), which is a composite endpoint of cardiovascular mortality, myocardial infarction and stroke, 2) clinically driven coronary, peripheral or carotid revascularization, and 3) stent thrombosis, that will be reported at 1 year.
The primary safety endpoint is major bleeding according to the International Society on Thrombosis and Haemostatsis (ISTH) criteria that will be reported at 1 year. It is a composite of 1) fatal bleeding, 2) symptomatic bleeding into a critical organ (such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome), 3) bleeding causing a fall in haemoglobin level of 2 g/dL (1.24 mmol/L) or more, or 4) leading to transfusion of two or more units of whole blood or red cells. |
one year | |
Secondary | Secondary Outcome Measures | The secondary efficacy and safety endpoint is the incidence of individual endpoints, that will be reported at 1 year:
Occurrence (and date) of stroke Occurrence (and date) of myocardial infarction Occurrence (and date) of cardiovascular death Occurrence (and date) of coronary revascularization procedures (PCI, CABG). Occurrence (and date) of peripheral revascularization procedures. Occurrence (and date) of carotid revascularization procedures. Occurrence (and date) of minor bleeding complications (according to ISTH) |
one year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05292079 -
CAPTURER PMCF Study ( rEPIC04D )
|
||
Recruiting |
NCT05292092 -
Essential Pro PMCF Study ( rEPIC04E )
|
||
Recruiting |
NCT05292118 -
Navitian PMCF Study ( rEPIC04C )
|
||
Recruiting |
NCT05292014 -
ANGIOLITE PMCF Study ( rEPIC04F )
|
||
Completed |
NCT05292105 -
NC Xperience PMCF Study( rEPIC04B)
|
||
Completed |
NCT01435031 -
EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions
|
N/A | |
Terminated |
NCT01443754 -
Hybrid Revascularisation by Combined Coronary Artery Bypass Graft (CABG) and PCI in Multivessel Coronary Disease
|
N/A | |
Completed |
NCT00783302 -
Study in Subjects Suspected of Having CAD Undergoing VISIPAQUE-enhanced CCTA as Part of Their Routine Medical Care
|
N/A | |
Completed |
NCT00543400 -
Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)
|
Phase 2 | |
Completed |
NCT05516784 -
Impact of CYP2C19 Genotype-guided Clopidogrel and Ticagrelor Treatment on Platelet Function Test and Metabolomics Profile
|
Phase 4 | |
Completed |
NCT02873052 -
MyoVista Measurements in Patients With Atherosclerosis and CAD
|
||
Terminated |
NCT02984891 -
Optical Coherence Tomography (OCT) Intravascular Ultrasound (IVUS) Dual Imaging
|
||
Completed |
NCT05292144 -
Xperience Pro PMCF Study
|
||
Completed |
NCT02554292 -
Post Market Surveillance of SeQuent Please Neo With Scoring Balloon
|
||
Active, not recruiting |
NCT06052319 -
A Study to Assess the Engagement and Usefulness of Care4Today Digital Platform for Disease Management in Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD) Population
|
||
Completed |
NCT00265525 -
Evaluation of a Web-based Intervention to Promote Physical Activity in Patients With Heart Disease.
|
Phase 3 | |
Completed |
NCT03570697 -
Imaging of Coronary Plaques in Participants Treated With Evolocumab
|
Phase 3 | |
Terminated |
NCT05508893 -
Screening for Coronary Artery Disease USing Primary Evaluation With Coronary CTA in Aviation Medicine (SUSPECT)
|
N/A | |
Completed |
NCT02341664 -
Patient and Provider Assessment of Lipid Management Registry
|
||
Completed |
NCT02098772 -
Phase III Study Comparing Two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N Versus Custodiol
|
Phase 3 |